Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.

Wellens J., Edmans M., Obolski U., McGregor CG., Simmonds P., Turner M., Jarvis L., Skelly D., Dunachie S., Barnes E., Eyre DW., Colombel J-F., Wong S-Y., Klenerman P., Lindsay JO., Satsangi J., Thompson CP.

More information

DOI

10.1136/gutjnl-2021-326312

Type

Journal article

Publication Date

01/09/2022

Volume

71

Pages

1919 - 1922

Total pages

3

Keywords

IBD, immune response, infectious disease, Antibodies, Monoclonal, Humanized, COVID-19, Humans, Immunoglobulin A, Inflammatory Bowel Diseases, Infliximab, SARS-CoV-2